2019 Annual Meeting | S3 - Epilepsy/Clinical Neurophysiology (EEG) I
Program Materials Program Evaluations
| Sudha Kessler, MD | Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Efficient CME. Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. The institution of Dr. Kessler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for The Epilepsy Study Consortium. Dr. Kessler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Kessler has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Wilson, Elser. The institution of Dr. Kessler has received research support from FDA, Commonwealth of Pennsylvania, Epilepsy Study Consortium, UCB Pharma, Greenwich Biosciences, Eisai Co. Ltd.. PCORI/AHRQ, SK Life. Dr. Kessler has a non-compensated relationship as a volunteer committee member with American Epilepsy Society that is relevant to AAN interests or activities. Dr. Kessler has a non-compensated relationship as a committee member with American Board of Psychiatry and Neurology that is relevant to AAN interests or activities. |
| Barbara C. Jobst, MD, PhD, FAAN | Dr. Jobst has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Jobst has received research support from Neuropace, Inc.. The institution of Dr. Jobst has received research support from Harvard Pilgrim. The institution of Dr. Jobst has received research support from NIH. The institution of Dr. Jobst has received research support from CDC. |
| Nilufer Taner, MD, PhD, FAAN | The institution of Dr. Taner has received research support from NIH. |
| Felicia Chu, MD | No disclosure on file |
| Marina K. Alvim | Dr. Alvim has nothing to disclose. |
| Brian Litt, MD | No disclosure on file |
| Mariet Allen, PhD | No disclosure on file |
| William O. Tatum IV, DO, FAAN | Dr. Tatum has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bioserenity. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Natus. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Tatum has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Defense Law Firm on behalf of a patient with epilepsy with funds donated to the Epilepsy Foundation of America. The institution of Dr. Tatum has received research support from Esai. The institution of Dr. Tatum has received research support from Mayo Clinic. The institution of Dr. Tatum has received research support from Liva Nova. The institution of Dr. Tatum has received research support from Engage Pharmaceuticals. The institution of Dr. Tatum has received research support from Xenon. Dr. Tatum has received intellectual property interests from a discovery or technology relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has received publishing royalties from a publication relating to health care. Dr. Tatum has a non-compensated relationship as a AAN Section Chair of Clinical Neurophysiology with AAN that is relevant to AAN interests or activities. |
| No disclosure on file | |
| George K. Vilanilam, MBBS | Dr. Vilanilam has nothing to disclose. |
| Gregory A. Worrell, MD | Dr. Worrell has received stock or an ownership interest from NeuroOne Inc.. Dr. Worrell has received stock or an ownership interest from Cadence Neuroscience Inc. The institution of Dr. Worrell has received research support from NIH. The institution of Dr. Worrell has received research support from Medtronic Inc.. The institution of Dr. Worrell has received research support from Neuropace Inc,. The institution of Dr. Worrell has received research support from Epilepsy Foundation of America. Dr. Worrell has received intellectual property interests from a discovery or technology relating to health care. Dr. Worrell has received intellectual property interests from a discovery or technology relating to health care. |
| Jake McKay, MD | Dr. McKay has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. |
| Anvita Potluri, MD | Dr. Potluri has nothing to disclose. |
| Yaretson I. Carmenate | No disclosure on file |
| Daniela R. Galluzzo, MD | Dr. Galluzzo has nothing to disclose. |
| Mary Jo Pugh, PhD, RN, FAAN | The institution of Dr. Pugh has received research support from Department of Defense, Epilepsy Research Program. The institution of Dr. Pugh has received research support from VA Health Services Research and Development Service. The institution of Dr. Pugh has received research support from VA Rehabilitation Research and Development Service. The institution of Dr. Pugh has received research support from Congressionally Directed Research Programs. The institution of Dr. Pugh has received research support from Sanofi. |
| Erie Gonzalez Gutierrez, MD | Dr. Gonzalez Gutierrez has nothing to disclose. |
| Eric D. Marsh, MD, PhD | Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmacuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from NIH. The institution of Dr. Marsh has received research support from Rett Syndrome Research Trust. The institution of Dr. Marsh has received research support from International Rett Syndrome Foundation. The institution of Dr. Marsh has received research support from Eagles Autism Challenge. The institution of Dr. Marsh has received research support from LouLou Foundation. The institution of Dr. Marsh has received research support from International CDKL5 Resarch Foundation. The institution of Dr. Marsh has received research support from Acadia Pharmaceuticals. The institution of Dr. Marsh has received research support from Marinus. The institution of Dr. Marsh has received research support from Stoke Therapeutics. The institution of Dr. Marsh has received research support from Takeda Pharmaceuticals. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Grant Review with NIH. Dr. Marsh has received personal compensation in the range of $5,000-$9,999 for serving as a Expert Witness with Department of Human Services. Dr. Marsh has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Medscape. |
| Samuel Tomlinson | No disclosure on file |
| Anteneh M. Feyissa, MD, MSc, FAAN | Dr. Feyissa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurelis. |
| Hamada H. Altalib, DO | The institution of Dr. Altalib has received research support from UCB. The institution of Dr. Altalib has received research support from Eisai. The institution of Dr. Altalib has received research support from Sunovian. The institution of Dr. Altalib has received research support from DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS. |
| Rana Hanna AL-Shaikh, MD | Dr. Hanna AL-Shaikh has nothing to disclose. |
| Kevan E. VanLandingham, MD, PhD, FAAN | Dr. VanLandingham has received personal compensation for serving as an employee of Greenwich Biosciences. Dr. VanLandingham has received stock or an ownership interest from Greenwich Biosciences. |
| Barry E. Gidal, PhD | Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai . Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Greenwich. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for SK life sciences . Dr. Gidal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Gidal has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for SK life science . |
| Heidi L. Henninger, MD, FAAN | Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. |
| Lindsay Schommer, NP | No disclosure on file |
| Lori Jensen | No disclosure on file |
| Marc De Backer, MD, FBCPM, MBA | No disclosure on file |
| Elinor Ben-Menachem, MD, FAAN | Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arvelle. Dr. Ben-Menachem has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharma. Dr. Ben-Menachem has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Acta Neurologica Scandinvica. The institution of Dr. Ben-Menachem has received research support from zogenic. |
| Teresa D. Gasalla, MD | Dr. Gasalla has received personal compensation for serving as an employee of UCB Biosciences Inc. Dr. Gasalla has stock in UCB Pharma. |
| Jeremy Wong, MD | Dr. Wong has nothing to disclose. |
| Fernando Cendes, MD, PhD, FAAN | Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy. The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP. The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico - Brazil . The institution of Dr. Cendes has received research support from NIH. |
| Steven S. Rosenfeld, MD, PhD | No disclosure on file |
| Marilise Katsurayama, MD | No disclosure on file |
| Gregory Krauss, MD | Dr. Krauss has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arvelle. Dr. Krauss has received stock or an ownership interest from EpiWatch. |
| Alfredo Quinones-Hinojosa | Alfredo Quinones-Hinojosa has nothing to disclose. |
| Jerzy P. Szaflarski, MD, PhD, FAAN | Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LivaNova Inc. Dr. Szaflarski has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Gidley, Sarli & Marusak, LLP. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Szaflarski has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Law Firm. Dr. Szaflarski has stock in AdCel Biopharma, LLC. Dr. Szaflarski has stock in iFovea. |
| Kathryn A. Davis, MD | Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals/Jazz Pharmaceuticals. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UNEEG. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Davis has received research support from Eisai. The institution of Dr. Davis has received research support from Liminal. Dr. Davis has received publishing royalties from a publication relating to health care. |
| Erin C. Conrad, MD | Dr. Conrad has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. Dr. Conrad has stock in Humana. Dr. Conrad has stock in Lilly Eli. Dr. Conrad has stock in Medtronic. Dr. Conrad has stock in Merck. Dr. Conrad has stock in Nevro. Dr. Conrad has stock in Sanofi. Dr. Conrad has stock in United Health Group. |
| Melissa Brock | No disclosure on file |
| Samantha Schmidt | No disclosure on file |
| Leticia Franceschet Ribeiro | No disclosure on file |
| Iscia Lopes-Cendes, MD, PhD | No disclosure on file |
| Clarissa L. Yasuda, MD, PhD | Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for LIBBS. Prof. Yasuda has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ABBOTT. Prof. Yasuda has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for LIBBS. |
| Victor Biton, MD | Dr. Biton has nothing to disclose. |